Restricted accessEditorialFirst published online 2012-10
The Search for Biomarkers of Disease: Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry,Tears,and Thyroid-Associated Ophthalmopathy
New England Congenital Hypothyroidism Collaborative. 1981. Effects of neonatal screening for hypothyroidism: prevention of mental retardation by treatment before clinical manifestations. Lancet, 2:1095–1098.
2.
GlassmanRH, RatainMJ. 2009. Biomarkers in early cancer drug development: limited utility. Clin Pharmacol Ther, 85:134–135.
3.
LiJ, ZhangZ, RosenzweigJ, WangYY, ChanDW. 2002. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem, 48:1296–1304.
4.
VergeCF, GiananiR, KawasakiE, YuL, PietropaoloM, JacksonRA, ChaseHP, EisenbarthGS. 1996. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes, 45:926–933.
5.
KhooDH, HoSC, SeahLL, FongKS, TaiES, CheeSP, EngPH, AwSE, FokAC. 1999. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid, 9:1175–1180.
6.
SinghRK, CooperTA. 2012. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med, 18:472–482.
7.
LiS, IakouchevaLM, MooneySD, RadivojacP. 2010. Loss of post-translational modification sites in disease. Pac Symp Biocomput, 2010:337–347.
PapandreouMJ, PersaniL, AsteriaC, RoninC, Beck-PeccozP. 1993. Variable carbohydrate structures of circulating thyrotropin as studied by lectin affinity chromatography in different clinical conditions. J Clin Endocrinol Metab, 77:393–398.
10.
WebsterJ, OxleyD. 2012. Protein identification by MALDI-TOF mass spectrometry. Methods Mol Biol, 800:227–240.
11.
MatheisN, OkrojekR, GrusFH, KahalyGJ. 2012. Proteomics of tear fluid in thyroid-associated orbitopathy. Thyroid, 22:1039–1045.
12.
BahnRS. 2010. Graves' ophthalmopathy. N Engl J Med, 362:726–738.
13.
PoonTC. 2007. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics, 4:51–65.
14.
ChangTC, HuangKM, ChangTJ, LinSL. 1990. Correlation of orbital computed tomography and antibodies in patients with hyperthyroid Graves' disease. Clin Endocrinol (Oxf), 32:551–558.
15.
KhalilHA, de KeizerRJ, KijlstraA. 1988. Analysis of tear proteins in Graves' ophthalmopathy by high performance liquid chromatography. Am J Ophthalmol, 106:186–190.
16.
DiasAC, ModuloCM, JorgeAG, BrazAM, JordaoAAJr, FilhoRB, de PaulaJS, RochaEM. 2007. Influence of thyroid hormone on thyroid hormone receptor beta-1 expression and lacrimal gland and ocular surface morphology. Invest Ophthalmol Vis Sci, 48:3038–3042.
17.
EcksteinAK, FinkenrathA, HeiligenhausA, Renzing-KohlerK, EsserJ, KrugerC, QuadbeckB, SteuhlKP, GieselerRK. 2004. Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies. Acta Ophthalmol Scand, 82:291–297.
18.
BakerGR, MortonM, RajapaskaRS, BullockM, GulluS, MazziB, LudgateM. 2006. Altered tear composition in smokers and patients with Graves ophthalmopathy. Arch Ophthalmol, 124:1451–1456.
19.
UjhelyiB, GogolakP, ErdeiA, NagyV, BalazsE, RajnavolgyiE, BertaA, NagyEV. 2012. Graves' orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines. Thyroid, 22:407–414.
GonzalezN, IloroI, DuranJA, ElortzaF, SuarezT. 2012. Evaluation of inter-day and inter-individual variability of tear peptide/protein profiles by MALDI-TOF MS analyses. Mol Vis, 18:1572–1582.
22.
DickinsonDP, ThiesseM. 1995. A major human lacrimal gland mRNA encodes a new proline-rich protein family member. Invest Ophthalmol Vis Sci, 36:2020–2031.
